Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001180 · ClinicalTrials.gov registry record

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

A clinical trial of Healthy and Cushing's Syndrome, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
2,250
Enrollment target
1
Study location

NCT00001180 is a study of Healthy and Cushing's Syndrome that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 2,250 participants, above the 645-participant average among 1,090 other Healthy trials with a reported enrollment target (249% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001180, a study of Healthy and Cushing's Syndrome, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
2,250 participants
Enrollment target
1
Study location

Study Summary

Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones. The order of amino acids in CRH, has been determined, meaning that the hormone can now be synthetically reproduced in a laboratory setting. When CRH is released from the hypothalamus it stimulates the pituitary gland to secrete another hormone, ACTH. ACTH then causes the adrenal glands to make a third hormone, cortisol. This process is known as the hypothalamic-pituitary-adrenal axis. Problems can occur in any of the steps of this process and result in a variety of diseases (Cushing's Syndrome and adrenal insufficiency). Researchers hope that CRH created in a laboratory setting, ovine CRH (oCRH) can be used to help diagnose and treat conditions of the HPA axis. This study will test the relationship for single doses of oCRH in normal volunteers and patients with disorders of the HPA axis. The oCRH will be injected into the patients vein as a single injection or slowly through an IV line over 24 hours. The participants will have blood tests taken to measure hormone levels before, during, and after receiving the oCRH.

Interventions

  • DRUG Ovine Corticotropin-Releasing Hormone (oCRH)

Study Locations (1)

Maryland

  • National Institute of Child Health and Human Development (NICHD) - Bethesda

Trial Details

FieldValue
Enrollment Target 2,250 participants
Start Date 1982-03
Est. Completion 2005-06

What the Registry Record Tells You About NCT00001180

The ClinicalTrials.gov registry entry for NCT00001180 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 645-participant average among 1,090 other Healthy trials with a reported enrollment target (249% higher). The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Ovine Corticotropin-Releasing Hormone (oCRH) is the first listed.

NCT00001180 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00001180 about?

NCT00001180 is a clinical study titled "Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency". Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones. The order of amino acids in CRH, has been determined, meaning that the hormone can now be synthetically reproduced in a ...

What is the current status of trial NCT00001180?

This trial is currently completed. The enrollment target is 2,250 participants. The study started on 1982-03. Estimated completion is 2005-06.

What conditions does trial NCT00001180 study?

This clinical trial studies the following conditions: Healthy, Cushing's Syndrome, Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction.

What interventions are being tested in trial NCT00001180?

The interventions under investigation include: Ovine Corticotropin-Releasing Hormone (oCRH) (DRUG).

Who is sponsoring clinical trial NCT00001180?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001180 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.